Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | CPA3 | P15088 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857365 | 0.85 | CYP1A2 (0.61) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL9748537 | 0.84 | CYP2C19 (0.50) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL7439419 | 0.83 | GRIK1 (0.64) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| Water SCHEMBL4010621 | 0.83 | CYP1A2 (0.59) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL7439193 | 0.83 | GRIK1 (0.64) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL7439191 | 0.83 | GRIK1 (0.64) | CYP1A2GRIK1CPA3LAP3ERAP2 | |
| SCHEMBL2396464 | 0.81 | CYP1A2 (0.70) | CYP1A2CPA3CPA1 | |
| SCHEMBL27636583 | 0.81 | SMN1; SMN2 (0.53) | ACEMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL1857647 | 0.80 | GRIK1 (0.60) | CYP1A2GRIK1 | |
| SCHEMBL1857645 | 0.80 | GRIK1 (0.60) | CYP1A2GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685248-B1 | OXIDOREDUCTASE FROM METSCHNIKOWIA ZOBELLII | IEP GMBH (DE) | 2010-06-09 | — | — | EP | claimed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | SMITH ROGER | 2009-10-08 | — | — | US | disclosed |
| CN-101198333-A | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2008-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | CYP1A2 98/4885ACE 777/4885GRIK1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.